Minervax Email Formats

Biotechnology Research • Copenhagen, Capital Region of Denmark, Denmark • 51-100 Employees

Minervax Email Formats

Minervax uses 1 email format. The most common is {2char} (e.g., {2char}@minervax.com), used 100% of the time.

Format	Example	Percentage
{2char}	{2char}@minervax.com	100%

Key Contacts at Minervax

Anna Laurén

Director Clinical Bioanalysis

Bjørn Kantsø

Chief Technology Officer, Head Of Cmc

Camilla Nawrocki

Senior Director Regulatory Affairs

Ida-Eline Vendelbo Meyhoff

Director, Clinical Operations

Per Fischer

Chief Executive Officer

Company overview

Headquarters	Ole Maaløes Vej 3, Copenhagen, Capital Region 2200, DK
Phone number	+4522114857
Website	minervax.com
SIC	283
Keywords	Group B Streptococcal And Gbs
Employees	51-100
Socials

About Minervax

MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability. Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.